# Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

> **NCT00516152** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 36 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia
- Acute Myelogenous Leukemia
- Myelodysplasia
- Acute Lymphocytic Leukemia
- Severe Aplastic Anemia
- Non-Hodgkin's Lymphoma
- Lymphoproliferative Disease
- Multiple Myeloma
- Advanced Myeloproliferative Disease

## Interventions

- **DRUG:** Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF

## Key facts

- **NCT ID:** NCT00516152
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2007-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2009-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00516152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00516152, "Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00516152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*